Skip to main content

Treatment of Human Coronavirus Infections using Alpha Glucosidase Glycoprotein Processing Inhibitors

Share:
Tech ID:
20-037
Principal Investigator:
Eric Holmes & Gary Ostrander
Licensing Manager:
Patents:
  • 17/180,140
Description:

Coronaviruses cause illness in adults and children ranging from the common cold to more severe diseases. Common signs of infection include respiratory symptoms, fever, cough, shortness of breath and breathing difficulties. In more severe cases, coronavirus infection can cause pneumonia, severe acute respiratory syndrome (SARS), kidney failure, and even death.

Coronaviruses are zoonotic, meaning they are transmitted between animals and humans. Several known coronaviruses are circulating in animals that have not yet infected humans. A novel coronavirus (nCo V) is a new strain that has not been previously identified in humans. There are currently no vaccines or antiviral drugs to prevent or treat human coronavirus infections.

The present invention concerns the use of alpha-glucosidase glycoprotein processing inhibitors for the treatment or prevention of human coronavirus infections.